Novo led the anaemia therapy developer's series A round, which also featured Access Industries subsidiary Access Biotechnology.
US-based haematology startup Disc Medicine closed a $50m series A round on Tuesday that was led by pharmaceutical firm Novo.
The round also featured Access Biotechnology, the biotech arm of diversified conglomerate Access Industries, as well as venture capital firm Atlas Venture, Disc Medicine’s founding investor, which had supplied an undisclosed amount of seed capital for the company in 2017.
Disc Medicine is developing treatments for haematologic diseases – those that affect the blood – based on the biology of…
